Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient - Test2 - elhamkhani - TriplyDB

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

http://www.wikidata.org/entity/Q57265316

about

Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease Therapeutic drug monitoring in inflammatory bowel disease Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium Optimizing the use of biological therapy in patients with inflammatory bowel disease The Role of Laboratory Tests in Crohn's Disease Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?Ulcerative colitis worsened after Clostridium difficile infection: efficacy of infliximab.Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.Significance of low level infliximab in the absence of anti-infliximab antibodies.A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels.Therapeutic drug monitoring in patients with inflammatory bowel disease Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease.Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure.Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn's Disease Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease.Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD Second Korean guidelines for the management of ulcerative colitis.Golimumab pharmacokinetics in ulcerative colitis: a literature review Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.Personalizing therapy for inflammatory bowel diseases.Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors.Targeting TNF-α for the treatment of inflammatory bowel disease.Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis.Tailoring anti-TNF therapy in IBD: drug levels and disease activity.Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives.Positioning therapy for Crohn's disease.TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease Review on modeling anti-antibody responses to monoclonal antibodies.Management of inflammatory bowel disease in poor responders to infliximab.

P2860

Q26745712-FCC03144-194C-46F8-AF06-A90366D04AE8 Q26745721-53C6E5C2-444D-4E4A-9521-15B2487EE59F Q26852729-A5F4664D-9210-42B2-AAF9-87BE036B81D6 Q27009385-F229E196-18AD-455F-AA88-06AF5EA60053 Q27025513-4F29B5EC-DABB-4901-AD31-6644E2416EB7 Q28075045-0E83A047-AE53-4236-AD39-16BE0CBBBB24 Q28079644-D0B1C080-0F5A-47B5-BE67-8DE0C7704CB1 Q30235581-6BA6D716-73A1-4BD8-A90E-71EB9E9F8F9B Q30995889-FA6AB3AE-9F13-40D6-95DE-76001923C8A3 Q33564263-019CA6C5-0550-4E13-B10D-A6BD30B22935 Q33874790-A93CAFB6-8535-4B75-AED4-AB55399B9343 Q35069511-E9ABB83A-ABDF-492F-B283-97BF973E671C Q35100143-4E59B1A2-2737-4109-AB24-7420A938ADAA Q35140715-715D7987-D025-466A-AB1A-815E92C13DE6 Q35213972-8F94ED03-16F8-4637-A3D2-6C3DF6501AEC Q35250578-8BFC87F9-BEB9-40F0-9719-CD6E167346B5 Q35561386-16D99DE0-E6F4-4228-A700-928891732474 Q35869305-6B9D5C2B-4C12-4855-B422-69271B6E3EE6 Q36150080-88D4DEB8-FAAE-4428-AF29-9531B44A7C2E Q36151324-E61943FB-B33E-42CA-8190-188DEB379415 Q36237186-B933B530-0283-48DA-BEF7-15EC9F9AE0D3 Q36347059-BA3F1930-CEF4-4073-B001-D8000EC98A31 Q36714704-C4CED0E5-4A89-47EB-B004-43168E6D1EFF Q36828605-81BCF074-DC2D-48DE-9F9E-C19BA02F726D Q36838066-07043F71-3E93-4136-953F-32863FD37016 Q37573910-22D6321F-F776-4216-9921-C5E08907680F Q37613845-B3E76EF6-DE20-452D-8186-C693B608E149 Q37662503-618448E5-FB8B-47BD-A5B6-FE340EFC1788 Q37671983-1558E7A7-7847-48A2-9C35-04CC68FD7D71 Q38121115-EE9B9C0B-18DE-4E7E-89AC-450C9A9885FC Q38132279-FBA3B918-942F-4820-8E74-29C4BE01D7DE Q38151885-64A7385B-5D71-4D53-AF5E-17136F116C36 Q38160905-0B657051-2967-4612-AEF7-0FE8A80D2144 Q38166552-929F9595-8F5F-4D0F-950D-23D9D2C01F26 Q38176154-CD43436F-59AE-42EC-A642-2F6FCE2D7EFF Q38193349-7C619667-F647-41A4-ACF9-934B06BEDC85 Q38200554-EB5D548C-3E41-4E6D-87E3-805F5EC28581 Q38206507-62FA36EF-E9C7-4049-9C08-53D95D67D378 Q38229813-94190512-A8CB-47B5-9168-DA857D44C423 Q38254573-C090598C-4D30-4888-9C41-95580D3D49B2

P2860

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

http://www.wikidata.org/entity/Q57265316

description

article

@en

im Februar 2013 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в лютому 2013

@uk

name

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

@en

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

@nl

type

label

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

@en

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

@nl

prefLabel

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

@en

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

@nl

P1433

Q57265316-4F32D398-48D9-43FB-8DA8-D75254A93742

P1476

Q57265316-F50C58A0-7E43-46AE-B480-849DC288C35E

P2093

Q57265316-0AA7BCDF-5285-4F09-9359-7781CF97F2A2

Q57265316-59305977-E82D-4BE6-9464-0023736D559E

Q57265316-7FB1341A-F6BE-4B08-913B-6739BA0DD300

Q57265316-88851B38-0AAA-447D-BBCA-AF09FFBC6D03

Q57265316-DDB2F007-59BE-4614-A87A-F7AEEF63F005

P2860

Q57265316-03DCE19F-5015-44AD-8CDD-52FB9B808C70

Q57265316-05CA0B87-42AE-410B-B64B-DDAEA82206DC

Q57265316-111BBF1C-7154-4E3E-ADF3-7EEC44433381

Q57265316-13BAC04E-B62E-4C7B-8F19-5433C417614C

Q57265316-155F7D1B-A83B-45DD-82E3-92D761E7A25B

Q57265316-21374DC1-1445-49F8-AFC6-94AFBDFAD75B

Q57265316-21A23422-FC0F-464E-BCB9-81A47BCD0286

Q57265316-410807D0-3361-4BC7-8EFC-5832FADD5252

Q57265316-57293B32-7161-4224-ABAA-D81CC6029900

Q57265316-86165529-771F-48E7-B973-3F20573036AF

P304

Q57265316-A5455910-E829-4C49-8A04-D81184C3850F

P31

Q57265316-ABF2337A-EEC3-40B3-8D17-5E38AC7BEE90

P356

Q57265316-79984A9E-6ADF-4272-B2EB-B129DE65F484

P407

Q57265316-4D7B6CED-C1C6-4D23-9457-8F7E66F83506

P433

Q57265316-C517CFFB-8762-4E2E-A33C-E6FB44B95905

P478

Q57265316-1605B0C9-C239-49B4-B7AC-6C2C13F9455A

P50

Q57265316-821A8B4D-6D56-4A8C-B5C1-B346FE5170D0

Q57265316-829E487D-590C-47D2-BC31-9809FFD00CF4

P577

Q57265316-767A0E0F-98CF-443C-BC57-B62B93617E85

P698

Q57265316-0F75E442-77F5-4D25-BFC3-3DDB5884B23D

P921

Q57265316-520E5F84-5ECA-4F11-9D02-C701BE2D9928

P356

P1433

The American Journal of Gastroenterology

P1476

Antibody response to infliximab and its impact on pharmacokinetics can be transient

@en

P2093

Ann Gils

http://www.w3.org/2001/XMLSchema#string

Linda Ohrmund

http://www.w3.org/2001/XMLSchema#string

Paul Rutgeerts

http://www.w3.org/2001/XMLSchema#string

Scott Hauenstein

http://www.w3.org/2001/XMLSchema#string

Sharat Singh

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Infliximab maintenance therapy for fistulizing Crohn's disease

Infliximab for induction and maintenance therapy for ulcerative colitis

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms.

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.

Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.

P304

962-971

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJG.2013.12

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Séverine Vermeire

Niels Vande Casteele

P577

2013-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23419382

http://www.w3.org/2001/XMLSchema#string

P921